Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Catheter-Based valve repair could help heart patients avoid surgery

NCT ID NCT03382457

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a device called the Edwards Cardioband FIT, which is used to repair the tricuspid valve in people with tricuspid regurgitation (a leaky heart valve). The device is delivered through a catheter, avoiding open-heart surgery. The trial includes 75 participants with moderate or worse tricuspid regurgitation who still have symptoms despite medical therapy. The goal is to see if the device is safe and effective at reducing the leak and improving symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Edwards Cardioband FIT Valve Repair System (a device implanted via catheter to repair the tricuspid valve)
What this could lead to
If it works, this could offer a less invasive treatment option for people with tricuspid regurgitation, reducing symptoms and the need for open-heart surgery.
What could go wrong
This is an early-stage study with only 75 participants, so results may not apply to everyone. The procedure carries risks like bleeding, infection, or device complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2018

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Tricuspid regurgitation (moderate or greater) * Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. * The local site Heart Team determines that the patient is appropriate for transcatheter tricuspid reconstruction * Patient is willing and able to comply with all specified study evaluations and provides written informed consent Key Exclusion Criteria: Patients with conditions or anatomical considerations that preclude safe and successful procedure-related or study device access, deployment, or function, including but not limited to: * Patients in whom transesophageal echocardiography is contraindicated or cannot be completed. * Patients in whom tricuspid valve anatomy is not evaluable by TTE or TEE * Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), polyester, or contrast media. * Previous tricuspid valve repair or replacement with device in place * Presence of trans-tricuspid pacemaker or defibrillator leads where: (a)TR is a result of impingement on the tricuspid valve leaflet as evaluated by echocardiography; or (b) implanted in the RV within the last 90 days Primary tricuspid valve disease Any physical impairment which limits the patient's capacity to complete functional testing due to other medical conditions independent of their TR (e.g., orthopedic condition) Currently participating in another investigational biologic, drug, or device study Any of the following cardiovascular procedures: * Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days * Carotid surgery within the last 30 days * Direct current cardioversion within the last 30 days * Leadless RV pacemaker implant within the last 30 days * Cardiac surgery within the last 90 days Any of the following underlying medical conditions: * Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation * Active endocarditis or infection requiring antibiotic therapy (oral or intravenous) * Hemodynamically significant pericardial effusion * Significant intra-cardiac mass, thrombus, or vegetation * Untreated clinically significant coronary artery disease (CAD) requiring revascularization, evidence of acute coronary syndrome, or recent myocardial infarction (MI) * Known history of untreated severe symptomatic carotid stenosis (\>50% by ultrasound) or asymptomatic carotid stenosis (\>70% by ultrasound) * Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or hemodynamic support within the last 30 days * Known bleeding or clotting disorders or patient refuses blood transfusion * Active GI bleeding * Recent stroke * Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months or any planned percutaneous cardiac procedure within the next 90 days * Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 6 months Pregnant, breastfeeding, or planning pregnancy within the next 12 months Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tricuspid regurgitation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Medical Center /New York Presbyterian Hospital

    New York, New York, 10032, United States

  • Heart Hospital Baylor Plano

    Plano, Texas, 75093, United States

  • Intermountain Medical Center

    Murray, Utah, 84107, United States

  • Lankenau Medical Center

    Wynnewood, Pennsylvania, 19096, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Morristown Medical Center

    Morristown, New Jersey, 07962, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Oregon Health & Science University

    Portland, Oregon, 97293, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.